Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 10 systematic review(s)/meta-analysis(es). ^[1-10]
• Ozanimod significantly reduced the annualized relapse rate (Bayesian Network Meta-Analyses for annualised relapse rate (ARR)) during the treatment period (relative risk (RR): -0.10 [95% confidence interval (CI): -0.15, -0.06]). Compared to teriflunomide, ozanimod further reduced ARR (RR: 0.73; 95% CI: 0.62-0.84).
• Ozanimod showed significant improvement in confirmed disability progression (adjusted indirect comparison to adjust for potential treatment effect modifiers and prognostic factors while assessing confirmed disability progression (CDP)) at 3 months compared to teriflunomide (hazard ratio (HR): 0.78; 95% CI: 0.66-0.92), but the effect was not significant at 6 months (HR: 0.78; 95% CI: 0.60-1.01). A similar pattern was observed compared to dimethyl fumarate, with significant improvement at 3 months (HR: 0.67; 95% CI: 0.53-0.86) but not at 6 months (RR: 0.89; 95% CI: 0.62-1.26).
• Alemtuzumab, ofatumumab, and ublituximab ranked higher for ARR than ozanimod, though ozanimod was categorized as moderate-to-high efficacy depending on the comparison approach.
• In ulcerative colitis (severe ulcerative colitis (UC)), ozanimod ranked lowest for induction of clinical response and remission at week 2 compared to upadacitinib and tofacitinib.
• Ozanimod was associated with a lower rate of adverse events (AEs) compared to control (RR: 0.64; 95% CI: 0.43–0.95), with a similar incidence of infection-related treatment-emergent AEs (nasopharyngitis and urinary tract infections) across groups.
• S1PR modulators, including ozanimod, significantly increased the risk of cardiovascular adverse events (RR: 2.21; 95% CI: 1.58–3.10), and ozanimod was linked with a higher risk of hypertension (RR: 1.76; 95% CI: 1.10–2.82).
• Compared with teriflunomide and dimethyl fumarate, ozanimod demonstrated significant reductions in overall AEs, serious AEs (SAEs), and discontinuations due to AEs.
• Studies included adults with relapsing-remitting multiple sclerosis (remitting multiple sclerosis (RRMS)) and moderate-to-severe UC. Gender distribution in relapsing-remitting multiple sclerosis (RRMS) participants was 68.6% female and 31.4% male. Ozanimod 1 mg showed superior efficacy over the 0.5 mg dose in RRMS without increasing adverse events.